News Release Detail

PRINCETON, N.J., July 08, 2021 (GLOBE NEWSWIRE) -- Certara, a global leader in biosimulation, today announced the release of BaseCase software version 2021.06, which updates the value communication software platform to include new capabilities that can provide biopharmaceutical and medical device companies greater commercial success for new therapies and products.

“In today's value-based healthcare environment, hard data guide reimbursement, prescribing, and procurement decisions,” said Daniel R. Matlis, founder and president of Axendia, a leading life science industry analyst firm. “These determinations are focused on demonstrating that a particular product delivers the best possible outcomes for a specific patient population at the most appropriate cost. As a result, the ability to easily build state-of-the-art, data-driven mobile apps, like BaseCase software, which enhance communication of value-based evidence, is paramount.”

The BaseCase software provides commercial, market access, and medical affairs teams a comprehensive, end-to-end environment to build state-of-the-art, interactive, data-driven mobile applications using multiple data sources, such as real-world data (RWD) and evidence (RWE). The BaseCase software enhances communications to demonstrate the value of therapies with payers, providers, and healthcare professionals. Currently, the platform is used in more than 60 countries by more than 30,000 users, including seven of the top 10 global biopharmaceutical companies and seven of the top 10 global medical device companies.

New capabilities of Certara’s BaseCase software include:

• Data Connect for connection to any data source and real-time updates
• Map Control for interactive maps, such as heat maps and maps of the human body
• Portal to easily develop and deploy mobile communication tools that demonstrate the value of a medical product
  

“The addition of Data Connect is a real breakthrough for Certara’s BaseCase software,” said Bridget Dunne, value communications team lead at Novartis. “It has significantly expanded our offerings and allows us to work with a wider range of customers. By connecting to live data feeds, regular data updates are automated, reducing timelines and workload significantly. It is secure and intuitive, and I’m excited to work on more projects of this kind.”

To learn more about BaseCase software, please go to: https://www.certara.com/evidence-access/basecase-value-communication-software/

About Certara
Certara accelerates medicines using biosimulation software and technology to transform traditional drug discovery and development. Its clients include more than 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries.

Certara Contact

Jieun W. Choe
jieun.choe@certara.com

Investor Relations Contact:
David Deuchler
Gilmartin Group
ir@certara.com

Media Contact:
Ariane Lovell
Finn Partners
ariane.lovell@finnpartners.com

Source: Certara